Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Sonelokimab in Active Psoriatic Arthritis
2021-005947-58Phase 2Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Oct 2022
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sonelokimab in psoriatic arthritis (PsA) (5 arms), sponsored by MoonLake Immunotherapeutics. Primary endpoint: ACR50 response at Week 12. Started Oct 2022; status: completed.
02
Drugs
sonelokimab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2021-005947-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005947-58.